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Abstract A quantitative structure–activity relationship study of tryptamine-based
derivatives of b1-, b2-, and b3-adrenoceptor agonists was conducted using com-
parative molecular ﬁeld analysis (CoMFA). Correlation coefﬁcients (cross-validated
r
2) of 0.578, 0.595, and 0.558 were obtained for the three subtypes, respectively, in
three different CoMFA models. All three CoMFA models have different steric and
electrostatic contributions, implying different requirements inside the binding
cavity. The CoMFA coefﬁcient contour plots of the three models and comparisons
among these plots provide clues regarding the main chemical features responsible
for the biological activity variations and also result in predictions which correlate
very well with the observed biological activity. Based on the analysis, a summary
regeospeciﬁc description of the requirements for improving b-adrenoceptor subtype
selectivity is given.
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Introduction
The b-adrenoceptor (b-AR), a member of the G-protein-coupled receptor (GPCR)
family, has been the object of several studies aimed at understanding its
physiological role and establishing structure–activity relationships for ligands
which bind selectively to speciﬁc subtypes (Bikker et al., 1998; Lefkowitz, 1998;
Wess, 1998; Schoneberg et al., 1999). b-ARs are widely distributed in the human
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RESEARCHbody and are found, for example, in the lung, heart, and adipose tissue. The b-AR
subtypes mediate several physiological processes including heart rate (Baker, 2005)
(b-1), bronchodilatation (Waldeck, 2002; Sears, 2001)( b-2), and lipolysis (Weyer
et al., 1999)( b-3). The b3-AR is involved in various pharmacological and
physiological effects including lipolysis, thermogenesis, and relaxation of intestinal
smooth muscle (deSouza and Burkey, 2001; Dow, 1997; Igawa et al., 1999). Agents
which selectively activate b3-ARs were proposed to be useful in the treatment of
obesity (Weyer et al., 1999), non-insulin-dependent diabetes mellitus, and frequent
urination. b3-AR agonists stimulate the intracellular signaling process to initiate the
lipolysis of triglycerides in white adipose tissue. The resulting free fatty acids are
processed by uncoupling protein, leading to thermogenesis in brown adipose tissue.
The glucose-lowering effect of b3-AR agonists is mediated through improved
peripheral insulin sensitivity. The exact mechanism of the antidiabetic action of this
class of compounds is not fully understood. Most of the previously developed
b3-AR compounds have suffered from one or more unacceptable pharmacokinetic or
pharmacodynamic problems, including lack of b3-AR selectivity, tissue speciﬁcity,
full agonist activity, drug toxicity, and a short plasma half-life (Arch and Wilson,
1996; Himms-Hagen and Danforth, 1996; Danforth and Himms-Hagen, 1997), as a
result of which no drug targeted to human the b3-AR has reached the market so far.
Hence attempts to identify clues for b3-AR selectivity are an urgent requirement.
Many structural classes of b3-adrenoceptor agonists have been developed;
prominent among these classes are the derivatives of arylethanolamine and
aryloxypropanolamine (Kordik and Reitz, 1999). The following are the important
leadsintheseseries:BRL-37344(Archetal.,1984),CL-316243(Bloometal.,1992),
BMS-201620 (Washburn et al., 2004), and L-749372 (Naylor et al., 1998). BRL-
37344 was reported to be a selective b3-AR partial agonist (b3 EC50 = 450 nM, 23%
activation)(Nayloretal.,1998).L-749372isalsoab3-ARpartialagonist(EC50 = 3.6
nM,33%activation),with270-and30-foldselectivityoverbindingtob1-andb2-ARs,
respectively (Naylor et al., 1998). The 4-piperidino-benzoic acid derivative CL-
316243 was found to be a modestly potent human b3-AR agonist (EC50 = 0.22 lM)
(Sum et al.,1999), and N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamide
(BMS-201620) a potent b3 full agonist (ki = 93 nM) (Washburn et al., 2004).
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1122 Med Chem Res (2010) 19:1121–1140A schematic diagram showing the important structural units considered for b3-
AR agonistic activity in recently reported molecules is given in Scheme 1. The
chirality at the hydroxyl center shows that (R) isomers possess the most favorable b3
potency and selectivity proﬁle over (S) isomers (Washburn et al., 2001). The aryl
group attached to the ethanolamine substructure is important for the biological
activity, which can be either phenyl (Nakajima et al., 2005), pyridine (Naylor et al.,
1999; Parmee et al., 1999), N-(2-hydroxy-phenyl)methanesulfonamide (Gavai et al.,
2001;H uet al., 2001c) or phenol (Parmee et al., 1998; Weber et al., 1998). b3-AR
agonist activity of 2,4-thiazolidinedione with several b-amino alcohols (R1) was
reported by Hu et al. (2001b). The amine portion of the ethanolamine group was
attached to the central aryl fragment by a two- or three-carbon atom spacer. The
central aryl linker fragment was replaced by a benzene (Naylor et al., 1998)o ri n d o l e
moiety (Harada et al., 2003). The central aromatic region was linked to the
sulfonamide group, which is understood to be essential for selectivity of b3-AR
agonistic activity (Uehling et al., 2002). Various research groups introduced acidic
functionality on R2 to increase the selectivity for b3-AR activity. In addition, they
suggested that the steric bulk of the R2 substituent also contributed to the potency and
selectivity of b3-AR agonists. However, it is thought that introduction of such
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Scheme 1 Essential pharmacophore elements present in b3-AR agonists, as identiﬁed from the reported
b3-selective arylethonolamine/aryloxypropanolamine derivatives
Med Chem Res (2010) 19:1121–1140 1123hydrophilic groups may generally cause low oral bioavailability, partly due to poor
absorption (van de Waterbeemd et al., 2001). Numbers of various bulky fragments
attached to R2 have been reported. These fragments are long chains with
oxadiazolidinedione (Hu et al., 2001d), thiazolidinediones (Hu et al., 2001a), urea
(Ashwell et al., 2001), triazole (Brockunier et al., 2000), oxazole (Ok et al., 2000),
oxadiazole (Feng et al., 2000; Biftu et al., 2000), thiazole (Mathvink et al., 2000), etc.
Molecular modeling studies offer several valuable tools for understanding the
interactions of drugs and their receptors on a molecular level (Silverman, 2004). In
the case of b-ARs very few molecular modeling studies have appeared to date. This
is mainly due to the absence of three-dimensional (3D) information about these
receptors. Some bold attempts have been made to computationally model the 3D
structure of these targets. Lybrand et al. reported 3D models for agonist and
antagonist complexes with b-adrenoceptors using computer modeling techniques
(Kontoyianni et al., 1996; Furse and Lybrand, 2003). Saxena and coworkers
reported 3D quantitative structure–activity relationship (QSAR) studies on a cyclic
ureidobenzenesulfonamides series of molecules using the Apex-3D method
(Kashaw et al., 2003; Prathipati and Saxena, 2005), and comparative molecular
ﬁeld analysis (CoMFA) and CoMSIA for different therapeutic areas (Gyanendra
et al., 2004; Stuti et al., 2004). Recently, we reported CoMFA studies on a
4-aminomethylpiperidine series of b3-AR agonists (Kumar and Bharatam, 2005). In
this paper we report comparative studies on the molecular ﬁeld requirements for a
tryptamine based series of molecules toward b1-, b2-, and b3-ARs. Kato and
coworkers reported the relative biological activities of tryptamine-based agonists
toward b1-, b2-, and b3-ARs and pointed out that the compounds may be more
speciﬁc to b3-ARs (Mizuno et al., 2004, 2005; Sawa et al., 2004, 2005). A set of 27
molecules from these series was employed in this work to carry out CoMFA studies
to identify relative steric and electronic requirements against these three receptors.
Computational details
All molecular modeling techniques and CoMFA studies were performed on a
Silicon Graphics Octane2 (R12000) workstation with an IRIX6.5 operating system
using the sybyl6.9 molecular modeling software package from Tripos, Inc. (St.
Louis, MO, USA, 2002).
Data sets
CoMFA was performed on a series of 27 tryptamine derivatives for which
biological activities (EC50 values) are reported with respect to b1-, b2-, and b3-ARs
(Harada et al., 2003; Mizuno et al., 2004, 2005; Sawa et al., 2004, 2005). The
structures and biological activity values of the 27 compounds forming the training
set and test set are listed in Table 1; they were assayed in one research laboratory
under the same experimental conditions. Only those compounds for which all three
biological activities toward b-ARs were available (i.e., b1, b2, and b3) were selected
from the published data. The EC50 is the concentration at which half the maximal
1124 Med Chem Res (2010) 19:1121–1140T
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Med Chem Res (2010) 19:1121–1140 1127response of the compound was observed. Biological activities are reported with
EC50 values ranging from 0.13 to 1700, 5.2 to 330, and 0.062 to 220 nM for human
b1-, b2-, and b3-ARs, respectively. The biological activities in the training set were
converted to pEC50 values of the agonists, which are the negative logarithms of the
molar concentration value, and used as dependent variables in the CoMFA.
Structure generation and alignment
Compounds in the training set were generated from the x-ray crystal structures or by
modiﬁcation of the crystal structure of similar compounds using the SYBYL
BUILD option (Tripos Inc. 2002). Conformation of compound 4 in the training set
was taken from the x-ray crystal structure reported on the same molecule as given in
the Cambridge Crystallographic Structural Database Centre (CCDC No. 203813)
(Harada et al., 2003). All remaining compounds were built from the crystal structure
of compound 4. Energy minimization was performed using the Tripos force ﬁeld
with a distance-dependent dielectric and conjugate gradient algorithm with a
convergence criterion of 0.005 kcal/mol. Partial atomic charges were calculated
using the Gasteiger–Huckel method (Gasteiger and Marsili, 1980). CoMFA studies
require that the 3D structures of the molecules to be analyzed be aligned according
to a suitable conformational template, which is assumed to be a ‘‘bioactive’’
conformation. Molecular alignment was carried out using the SYBYL ‘‘ﬁt-atom’’
alignment function (Tripos Inc. 2002). The crystal structure of compound 4 was
used as the alignment template. Figure 1 shows the 3D alignment of 27 molecules
according to the alignment scheme in Fig. 2.
CoMFA study
The CoMFA descriptors were used as independent variables, and pEC50 values
where used as dependent variables, in partial least squares (PLS) (Wold et al., 1984)
regression analysis to derive 3D QSAR models. The steric (Lennard-Jones) and
electrostatic (Coulomb) CoMFA ﬁelds were calculated using an sp
3 carbon as the
steric probe atom and a ?1 charge for the electrostatic probe. A grid spacing of 2 A ˚
and a distance-dependent dielectric constant were chosen. The cutoff value for both
steric and electrostatic interactions was set to 30 kcal/mol.
Fig. 1 The 3D alignment of the 27 molecules is shown by capped sticks without hydrogens
1128 Med Chem Res (2010) 19:1121–1140Partial least squares analysis
PLS regression analyses were performed using cross-validation to evaluate the
predictive ability of the CoMFA models. Initial PLS regression analyses were
performed in conjunction with the cross-validation (leave-one-out method) option to
obtain the optimal number of components to be used in the subsequent analysis of
the dataset. All the leave-one-out cross-validated PLS analyses were performed with
a column ﬁlter value of 2.0 kcal/mol to improve the signal-to-noise ratio by
omitting those lattice points whose energy variation was below this threshold value.
The ﬁnal PLS regression analysis with 10 bootstrap groups and the optimal number
of components was performed on the complete dataset. The optimal number of
components was determined by selecting the smallest PRESS value. Usually this
value corresponds to the highest cross-validated r2 r2
cv
  
value. The r2
cv was
calculated using the formula
r2
cv ¼ 1  
P
Ypredicted   Yobserved
   2
P
Yobserved   Ymean ðÞ
2
where Ypredicted, Yobserved, and Ymean are the predicted, actual, and mean values of the
target property (pEC50), respectively. The number of components obtained from the
cross-validated analysis was subsequently used to derive the ﬁnal QSAR models. In
addition to r2
cv, the corresponding PRESS [PRESS =
P
(Ypredicted - Yobserved)
2], the
number of components, the nonconventional correlation coefﬁcient r2
ncv, and its
standard errors were also computed.
Test sets
To test the predictive power of the CoMFA model, seven agonists from the b1-
and b2-AR subtypes and ﬁve agonists from the b3-AR subtype were selected as
the test set (Table 2). The agonists in the test set were chosen by random
sampling of biological activity. The conformation, minimization, and alignment
of these agonists in the test set were obtained by the same protocol as that
described for the agonists in the training set used. All predicted activities for test-
set molecules were calculated using the optimized CoMFA model. The results of
the non-cross-validated calibration model on the test sets are summarized in
Table 3.
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Fig. 2 Molecule 4 with atoms
used for superimposition are
named 1 to 7
Med Chem Res (2010) 19:1121–1140 1129Predictive r
2 values
The predictive r2 r2
pre
  
was based only on molecules not included in the training set
and is deﬁned as explained by Marshall and co-workers (Oprea et al., 1994; Waller
et al., 1993).
Table 2 Experimental (exp) and predicted (pre) biological activities along with estimated residual
values (res) of training- and test-set molecules (log 1/EC50) 9 10
-9 associated with the three CoMFA
models b1, b2, and b3
Molecule b1 b2 b3
Exp Pre Res Exp Pre Res Exp Pre Res
1 8.72 7.66 1.06 7.60 6.38 1.22 8.26 6.99 1.27
2 7.32 7.26 0.06 6.48 6.42 0.06 6.65 6.61 0.04
3 9.88 7.69 2.19 8.28 6.64 1.64 9.44 6.91 2.53
4 8.19 8.17 0.02 7.88 6.59 1.29 10.20 7.27 2.93
5 5.76 7.76 –2.0 6.53 6.59 –0.06 7.67 7.28 –0.01
6 7.67 7.68 –0.01 7.18 7.20 –0.02 9.05 9.12 –0.07
7 8.18 8.18 0.00 7.53 7.44 0.09 9.25 9.21 0.04
8 8.18 8.24 –0.06 7.26 7.29 –0.03 9.11 9.06 0.05
9 8.16 8.69 –0.53 7.72 7.76 –0.04 8.88 8.93 –0.05
10 7.72 7.90 –0.18 6.74 7.33 –0.59 8.76 8.70 0.06
11 7.74 8.05 –0.31 7.35 7.36 –0.01 9.67 9.59 0.08
12 8.13 8.19 –0.06 7.58 7.37 0.21 9.22 9.24 –0.02
13 8.25 8.18 0.07 7.69 7.69 0.0 9.55 9.53 0.02
14 8.20 8.26 –0.06 7.39 7.42 0.03 9.29 9.33 –0.04
15 8.50 8.64 –0.14 7.14 7.24 –0.10 9.06 9.15 –0.09
16 8.88 8.87 0.01 7.65 7.24 0.41 9.58 9.39 0.19
17 8.92 8.88 0.04 7.30 7.31 –0.01 9.19 9.21 –0.02
18 8.14 8.39 –0.25 7.23 7.20 0.03 8.92 8.95 –0.03
19 7.88 7.82 0.06 7.58 7.66 –0.08 9.32 9.34 –0.02
20 7.72 7.71 0.01 7.88 7.73 0.15 9.26 9.19 0.07
21 7.16 7.19 –0.03 6.92 7.70 –0.78 6.79 9.19 –2.4
22 8.00 8.03 –0.03 6.76 6.79 –0.03 8.92 7.67 1.25
23 8.00 8.08 –0.08 6.79 6.72 0.07 7.44 7.41 0.03
24 8.01 7.16 0.85 7.34 7.34 0.0 8.00 8.00 0.0
25 8.11 8.11 0.00 7.35 7.36 –0.01 8.53 8.54 –0.01
26 7.65 7.66 –0.01 7.49 7.50 –0.01 8.35 8.38 –0.03
27 7.35 7.36 –0.01 7.29 7.34 –0.05 9.00 9.07 –0.07
Note: b1-AR: training set, 2, 4, 6–8, 12–14, 16, 17, 19–22, 25–27; test set, 9–11, 15, 18, 23, 24; outliers, 1,
3, 5. b2-AR: training set, 2, 5–9, 11, 13, 15, 18–20, 22–26; test set, 10, 12, 14, 16, 17, 21, 27; outliers, 1, 3,
4. b3-AR: training set, 2, 5–7, 9, 11–13, 15–17, 19, 23–27; test set, 8, 10, 14, 18, 20; outliers, 1, 3, 4, 21,
22
1130 Med Chem Res (2010) 19:1121–1140r2
pre ¼ SD   PRESS ðÞ =SD
where SD is the sum of the squared deviations between the biological activities of
molecules in the test set and the mean activity of the training-set molecules, and
PRESS is the sum of the squared deviations between predicted and actual biological
activity values for every molecule in the test set. This is analogous to Cramer’s
deﬁnition: whenever PRESS is larger than SD, this results in a negative value
reﬂecting complete lack of predictive ability of the training set for the molecules
included in the test set (Cramer et al., 1988).
Results
CoMFA of the b1-adrenoceptor
PLS analysis was used in combination with cross-validation to obtain the optimal
number of components to be used in the subsequent non-cross-validation analysis.
PLS analysis based on least squares ﬁt gave a correlation with a cross-validated r2
cv
of 0.578, with the maximum number of components set equal to ﬁve. The non-cross-
validated PLS analysis was repeated with the ﬁve components, giving an r2
ncv of
0.993. To obtain statistical conﬁdence limits, the non-cross-validated analysis was
repeated with 10 bootstrap groups, which yielded an r
2 of 0.996 (ﬁve components,
SEE = 0.027, std dev = 0.003, steric contribution = 0.558, and electrostatic
contribution = 0.442). These parameters are listed in Table 3. The above satisfac-
tory cross-validated correlation coefﬁcient indicates that the CoMFA model is
highly reliable. The high bootstrapped r
2 value and low standard deviation suggest a
high degree of conﬁdence in the analysis. The calculated biological activities
obtained from the analysis are plotted versus the actual values in Fig. 3a.
Compounds 9, 10, 11, 15, 18, 23, and 24 (test set) were used to evaluate the
Table 3 Statistical parameters associated with the three CoMFA models b1, b2, and b3
Parameter b1 b2 b3
N 17 17 17
No. components 5 5 6
r2
cv 0.578 0.595 0.558
r2
ncv 0.993 0.976 0.995
Ftest 305.3 90.5 310.7
r2
bs 0.996 0.997 0.999
r2
pre 0.847 0.607 0.758
Std dev (bs) 0.003 0.003 0.001
SEE 0.027 0.023 0.033
Steric ﬁeld contribution 0.558 0.394 0.401
Electrostatic ﬁeld contribution 0.442 0.606 0.599
Note: N, number of compounds; r2
cv, cross-validation by leave-one-out method; r2
ncv, non-cross-validation;
r2
bs, 10 bootstrapping runs; r2
pre, predictive r
2; SEE, standard error of estimate
Med Chem Res (2010) 19:1121–1140 1131predictive power of this CoMFA model. As in the calibration step, a good predictive
ability, with an r2
pre ¼ 0:847, for the compounds in the test set was obtained. Table 2
reports that the predicted values fall close to the observed biological activity value,
deviating by less than one logarithmic unit.
The b1 CoMFA steric and electrostatic ﬁelds from the ﬁnal non-cross-validated
analysis are plotted as three-dimensional color contour maps in Figs. 4a and 5a,
respectively, along with the reference compound, 16. These contour maps indicate
the regions where differences in molecular ﬁelds are associated with differences in
biological activity. Green contours indicate regions in which increasing steric bulk
is tolerable, and yellow contours indicate regions in which the steric bulk decreases
the activity. In the b1 model the steric contours show that the substituents attached
to the ring of the arylethanolamine group are placed in sterically unfavorable
regions. Of the four yellow contours near the arylethanolamine group three of them
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Fig. 3 A graph of experimental
vs. predicted activities of the
training-set and test-set
molecules as b1-AR (a), b2-AR
(b), and b3-AR (c) agonists. ( )
Training set; ( ) test set
1132 Med Chem Res (2010) 19:1121–1140are below the local plane of the reference compound and one is above the ﬁve-
membered ring of the reference compound. These yellow regions indicate that
additional steric interactions in these regions would lead to decreased biological
activity. The above observations indicate that for good b1-agonistic activity there
should be only very small groups or no substituents on the aryl ring of
arylethanolamine. These can account for a limiting size and shape for the
substituents that would be effective for tight binding to the receptor. A big yellow
contour above the indole ring indicates that any substituents on the nitrogen of the
Fig. 4 CoMFA steric STDEV*COEFF contour plots of the tryptamine-based derivative training set
generated for the b1 (a), b2 (b), and b3 (c) models. Compounds 16 (a, c) and 20 (b) are shown inside the
ﬁeld
Med Chem Res (2010) 19:1121–1140 1133indole ring would greatly reduce the biological activity, suggesting limited bulk
tolerance. The small green region at the C7 position of the indole nucleus indicates
that increases in the steric bulk at this position are marginally favorable for b1-AR
activity. The electrostatic contour map (Fig. 5a) of the CoMFA model shows a
small blue contour near the SO2 group attached to arylethanolamine and red
contours near the C7 substituents on the indole ring. This indicates that a reduction
in the electronegativity near the SO2 group and increasing electronegativity at the
C7 position of indole should lead to increased b1 activity.
Fig. 5 CoMFA electrostatic STDEV*COEFF contour plots of the tryptamine-based derivative training
set generated for the b1 (a), b2 (b), and b3 (c) models. Compounds 16 (a, c) and 20 (b) are shown inside
the ﬁeld
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The b2 CoMFA analysis based on the ﬁt atom alignment yielded good cross-
validated (r2
cv ¼ 0:595) and conventional r2 r2 ¼ 0:976: F   test value ¼ 90:518 ðÞ ,
with the optional number of components found to be ﬁve. The steric and
electrostatic ﬁelds contribute to the QSAR equation by 39.4% and 60.6%,
respectively. A high bootstrapped (10 sampling) r2
bs value of 0.997 (SEE =
0.023, std dev = 0.003) was found. A plot of actual versus calculated biological
activity obtained from the analysis is given in Fig. 3b. Compounds 10, 12, 14, 16,
17, 21, and 27 (test set) were used to evaluate the predictive power of this CoMFA
model. A good predictive ability, with an r2
pre ¼ 0:607, for the compounds in the test
set was obtained in this calibration step. Table 2 reports that the predicted values
fall close to the observed biological activity value, deviating by less than one
logarithmic unit.
The b2 CoMFA steric and electrostatic ﬁelds from the ﬁnal non-cross-validated
analysis are plotted in Figs. 4b and 5b respectively. The most active compound, 20,
was treated as the reference molecule. The graphical interpretation of the ﬁeld
contribution of the steric contour map is shown in Fig. 4b. The steric contour map
shows three yellow regions surrounding the phenyl unit in the NHSO2Ph group, and
a small green at the para position on the same ring. This indicates that it is
preferable to reduce the steric bulk due to the Ph group. The presence of a simple
thiophen ring, as in many other molecules in this series, is preferable for b2 activity.
A very large yellow contour is noted near the C7 of the indole ring in Fig. 4b,
indicating that the steric bulk should be reduced for improved b2 activity. The
CoMFA electrostatic contour map displays a large blue region surrounding the
SO2Ph group and two small red regions in close proximity, suggesting that a strong
reduction in the electronegative groups is preferred in this region. There are two
small blue regions and one small red region at the C7 of the indole ring of the
reference compound. The distribution range of blue is higher than that of red,
indicating that electropositive groups in this region are very important for the b2
biological activity.
CoMFA of the b3-adrenoceptor
The b3 CoMFA analysis based on the ﬁt atom alignment yielded acceptable cross-
validated (r2
cv ¼ 0:558) and conventional results (r2 ¼ 0:995;F   test value ¼
310:717), with the optimal number of components found to be six. In this model,
steric and electrostatic ﬁelds contribute to the QSAR equation by 40.1% and 59.9%,
respectively. The high bootstrapped (10 sampling) r2
bs value of 0.999 (SEE = 0.033,
std dev = 0.001) was found. Compounds 8, 10, 14, 18, and 20 (test set) were used to
evaluate the predictive power of this CoMFA model. The predicted versus the actual
values of biological activities obtained from the analysis are plotted in Fig. 3c. The
b3 CoMFA model shows a very good predictive ability, with r2
pre ¼ 0:758 for the
compounds in the test set, as obtained for the calibration steps. Table 2 shows that
the predicted values fall close to the observed biological activity value, deviating by
less than one logarithmic unit.
Med Chem Res (2010) 19:1121–1140 1135The steric and electrostatic contour maps obtained from the b3 CoMFA model are
shown in Figs. 4c and 5c, respectively, along with compound 16. In Fig. 4c, the
steric contour map shows a large green region around the substituent on the aryl
ring, indicating the presence of a b3-AR binding pocket which can accommodate
bulky substituents of large size, such as isopropyl and t-butyl. The presence of a
bulky substituent at the indole ring decreases activity because of steric hindrance, as
indicated by the yellow contour. Figure 5c shows a huge blue contour near the
thiophen ring, indicating that decreasing electronegative character/increasing
electropositive character is an important consideration in this region for improved
b3-agonistic activity.
Discussion
Three different 3D QSAR models have been developed using the CoMFA
methodology for tryptamine-based analogues of b-AR agonists. This is a ﬁrst
attempt to describe quantitatively the hypothetical receptor binding site of multiple
subtypes of b-ARs. Comparison of the three CoMFA models helps in understanding
b-AR selectivity. The main steric and electrostatic interactions on the binding cavity
of b1-, b2-, and b3-ARs are demonstrated in Scheme 2. The 3D QSAR CoMFA of
these b-AR subtypes led to the following considerations:
The b2 and b3 CoMFA models show similarities in their overall steric and
electrostatic contributions. In the b1 CoMFA model the steric contribution is larger,
whereas in the b2 and b3 CoMFA models the electrostatic contribution is larger (see
Table 3). Detailed CoMFA contour map analysis shows that decreasing steric bulk
is preferable for increased b1 and b2 activity near the sulfonamide unit. On the other
hand, increasing steric bulk is preferable for the b3-AR activity near the phenyl
H
N
OH
N
H
S
O O
RHS
LHS
Increasing steric bulk is
favourable for β3 specificity
Decreasing steric bulk is
favourable for β1and β2 specificity
Increasing electronegative charater
favours β1 specificity
Decreasing electronegative charater
favours β3 and β2 specificity
Decreasing steric bulk is
favourable for β1and β2 specificity
Increasing steric bulk is
favourable for β3 specificity
Increasing electropositive
character on substituent is
favorable for β3 specificity
Scheme 2 Proposed hypothetical receptor model of b-Ars binding site
1136 Med Chem Res (2010) 19:1121–1140sulfonamide unit. Strong yellow contours are observed near the C7 unit of the indole
ring in all three CoMFA models, indicating that smaller functional units are
preferable in this region. From this information, it may be inferred that the active
site of b3-AR can accommodate large substituents on the left-hand side for tight
binding. Thus, b3-selectivity of this series of compounds can be brought about by
employing large groups on the phenyl unit of phenyl sulfonamide in 16.I ti s
preferable to reduce the steric effects on the C7 of the indole ring in 16 for all (b1,
b2, b3) activities. Figure 5 shows that there are distinguishable differences in the
electrostatic ﬁelds of b1, b2, and b3 CoMFA models. In all the models, increasing
electropositive character is preferred near the SO2Ar unit in 16, the inﬂuence of
which increased in the order b1\b2\b3. This requirement is very strong for b3-
agonistic activity. Thus, large substituents with a strong electropositive character on
the Ar unit of SO2Ar are required for b3 speciﬁcity. On the other hand, electrostatic
factors appear to be optimum for b3 activity on the right-hand side of Scheme 2.
However, increasing electronegative substituents are favorable for b1 activity and
increasing electropositive character is favorable for b2 selectivity. These factors are
summarized in Scheme 2. In summary, the absence of information on the
experimental binding mode of these agonists toward their b-ARs, the binding
mode information obtained for the comparative 3D QSAR studies shall be helpful in
modulating the tryptamine series of molecules for selectivity against b1, b2, and b3
activities.
Conclusion
In this paper, we have established CoMFA models for a series of tryptamine-based
analogues for various subtypes of b-AR agonists, i.e., b1-, b2-, and b3-AR agonists.
Three different 3D QSAR models have been established for b1-AR, b2-AR, and
b3-AR agonistic activities in a series of tryptamine molecules using the CoMFA
method. All three models show satisfactory statistical signiﬁcance values r2
cv (0.578,
0.575, 0.558), SEE (0.027, 0.023, 0.033), etc. Comparative study of the steric and
electrostatic contour maps provided clues to the chemical modulations required for
improving speciﬁcity. For b3-speciﬁcity, for example, increased steric bulk and
increased electropositive character are required on the aryl group of the SO2Ar unit
in this series of molecules. Based on the present 3D QSAR CoMFA studies, a
hypothetical receptor model of these agonists with the b3-AR is proposed (see
Scheme 2). Since information related to the 3D structure of the active site of the
three b-ARs is not available, information provided in this article in the form of
molecular ﬁeld requirement shall be of help in designing selective b3-AR agonists.
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